Impact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population-based cohort of stage I–II breast cancers

BACKGROUND: Reductions in the dose intensity (DI) of adjuvant anthracycline-based chemotherapy in early stage breast cancer are frequently required due to treatment toxicity or poor tolerance, but the implications of a minimal reduction in DI on clinical outcome remain uncertain. PATIENTS AND METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Tinker, AV, Speers, C, Barnett, J, Olivotto, IA, Chia, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234069/
https://www.ncbi.nlm.nih.gov/pubmed/22275960
http://dx.doi.org/10.3332/eCMS.2008.63

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234069/
https://www.ncbi.nlm.nih.gov/pubmed/22275960
http://dx.doi.org/10.3332/eCMS.2008.63

Ejemplares similares